{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:15:28Z","timestamp":1787987728903,"version":"build-2784847793"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Neonatal hypoglycemia is an important preventable cause of neurodevelopmental impairment, but there is a paucity of evidence to guide treatment.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate whether early, low-dose oral diazoxide for severe or recurrent neonatal hypoglycemia reduces time to resolution of hypoglycemia.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This 2-arm, placebo-controlled randomized clinical trial was conducted from May 2020 to February 2023 in tertiary neonatal units at 2 New Zealand hospitals. Participants were neonates born at 35 or more weeks\u2019 gestation and less than 1 week of age with severe hypoglycemia (blood glucose concentration &amp;lt;22 mg\/dL or &amp;lt;36 mg\/dL despite 2 doses of dextrose gel) or recurrent hypoglycemia (\u22653 episodes of a blood glucose concentration &amp;lt;47 mg\/dL within 48 hours).<\/jats:p><\/jats:sec>Interventions<\/jats:title>Newborns were randomized 1:1 to receive diazoxide suspension (loading dose, 5 mg\/kg; maintenance, 1.5 mg\/kg every 12 hours) or placebo, titrated per protocol.<\/jats:p><\/jats:sec>Main Outcome and Measures<\/jats:title>The primary outcome was time to resolution of hypoglycemia, defined as enteral bolus feeding without intravenous fluids and normoglycemia (blood glucose concentration of 47-98 mg\/dL) for at least 24 hours, compared between groups using adjusted Cox proportional hazards regression. Hazard ratios adjusted for stratification variables and gestation length are reported. Prespecified secondary outcomes, including number of blood glucose tests and episodes of hypoglycemia, duration of hypoglycemia, and time to enteral bolus feeding and weaning from intravenous fluids, were compared by generalized linear models. Newborns were followed up for at least 2 weeks.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 154 newborns screened, 75 were randomized and 74 with evaluable data were included in the analysis (mean [SD] gestational age for the full cohort, 37.6 [1.6] weeks), 36 in the diazoxide group and 38 in the placebo group. Baseline characteristics were similar: in the diazoxide group, mean (SD) gestational age was 37.9 (1.6) weeks and 26 (72%) were male; in the placebo group, mean (SD) gestational age was 37.4 (1.5) weeks and 27 (71%) were male. There was no significant difference in time to resolution of hypoglycemia (adjusted hazard ratio [AHR], 1.39; 95% CI, 0.84-2.23), possibly due to increased episodes of elevated blood glucose concentration and longer time to normoglycemia in the diazoxide group. Resolution of hypoglycemia, when redefined post hoc as enteral bolus feeding without intravenous fluids for at least 24 hours with no further hypoglycemia, was reached by more newborns in the diazoxide group (AHR, 2.60; 95% CI, 1.53-4.46). Newborns in the diazoxide group had fewer blood glucose tests (adjusted count ratio [ACR], 0.63; 95% CI, 0.56-0.71) and episodes of hypoglycemia (ACR, 0.32; 95% CI, 0.17-0.63), reduced duration of hypoglycemia (adjusted ratio of geometric means [ARGM], 0.18; 95% CI, 0.06-0.53), and reduced time to enteral bolus feeding (ARGM, 0.74; 95% CI, 0.58-0.95) and weaning from intravenous fluids (ARGM, 0.72; 95% CI, 0.60-0.87). Only 2 newborns (6%) treated with diazoxide had hypoglycemia after the loading dose compared with 20 (53%) with placebo.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this randomized clinical trial, early treatment of severe or recurrent neonatal hypoglycemia with low-dose oral diazoxide did not reduce time to resolution of hypoglycemia but reduced time to enteral bolus feeding and weaning from intravenous fluids, duration of hypoglycemia, and frequency of blood glucose testing compared with placebo.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ANZCTR.org.au Identifier: ACTRN12620000129987<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.15764","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T15:21:55Z","timestamp":1718292115000},"page":"e2415764","source":"Crossref","is-referenced-by-count":7,"title":["Diazoxide for Severe or Recurrent Neonatal Hypoglycemia"],"prefix":"10.1001","volume":"7","author":[{"given":"Don","family":"Laing","sequence":"first","affiliation":[{"name":"Liggins Institute, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eamon P. G.","family":"Walsh","sequence":"additional","affiliation":[{"name":"Liggins Institute, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane M.","family":"Alsweiler","sequence":"additional","affiliation":[{"name":"Department of Paediatrics: Child and Youth Health, University of Auckland, Auckland, New Zealand"},{"name":"Te Whatu Ora Te Toka Tumai Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Hanning","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Meyer","sequence":"additional","affiliation":[{"name":"Kidz First Neonatal Care, Te Whatu Ora Counties Manukau, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julena","family":"Ardern","sequence":"additional","affiliation":[{"name":"Kidz First Neonatal Care, Te Whatu Ora Counties Manukau, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne S.","family":"Cutfield","sequence":"additional","affiliation":[{"name":"Liggins Institute, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Rogers","sequence":"additional","affiliation":[{"name":"Liggins Institute, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Gamble","sequence":"additional","affiliation":[{"name":"Liggins Institute, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Geoffrey","family":"Chase","sequence":"additional","affiliation":[{"name":"Department of Mechanical Engineering, University of Canterbury, Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane E.","family":"Harding","sequence":"additional","affiliation":[{"name":"Liggins Institute, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J. D.","family":"McKinlay","sequence":"additional","affiliation":[{"name":"Department of Paediatrics: Child and Youth Health, University of Auckland, Auckland, New Zealand"},{"name":"Kidz First Neonatal Care, Te Whatu Ora Counties Manukau, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"issue":"11","key":"zoi240529r1","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1001\/jamapediatrics.2023.3957","article-title":"Infants eligible for neonatal hypoglycemia screening: a systematic review.","volume":"177","author":"O\u2019Brien","year":"2023","journal-title":"JAMA Pediatr"},{"issue":"7","key":"zoi240529r2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2352-4642(20)30387-4","article-title":"Strategies to improve neurodevelopmental outcomes in babies at risk of neonatal hypoglycaemia.","volume":"5","author":"Alsweiler","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"issue":"10","key":"zoi240529r3","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1001\/jamapediatrics.2017.1579","article-title":"Association of neonatal glycemia with neurodevelopmental outcomes at 4.5 years.","volume":"171","author":"McKinlay","year":"2017","journal-title":"JAMA Pediatr"},{"issue":"10","key":"zoi240529r4","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jamapediatrics.2015.1631","article-title":"Association between transient newborn hypoglycemia and fourth-grade achievement test proficiency: a population-based study.","volume":"169","author":"Kaiser","year":"2015","journal-title":"JAMA Pediatr"},{"issue":"16","key":"zoi240529r5","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1504909","article-title":"Neonatal glycemia and neurodevelopmental outcomes at 2 years.","volume":"373","author":"McKinlay","year":"2015","journal-title":"N Engl J Med"},{"key":"zoi240529r6","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1071206","article-title":"New approaches to screening and management of neonatal hypoglycemia based on improved understanding of the molecular mechanism of hypoglycemia.","volume":"11","author":"Stanley","year":"2023","journal-title":"Front Pediatr"},{"issue":"5","key":"zoi240529r7","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/s41372-020-00891-w","article-title":"Prolonged transitional neonatal hypoglycaemia: characterisation of a clinical syndrome.","volume":"41","author":"Bailey","year":"2021","journal-title":"J Perinatol"},{"issue":"8","key":"zoi240529r8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-059452","article-title":"Oral diazoxide versus placebo for severe or recurrent neonatal hypoglycaemia: Neonatal Glucose Care Optimisation (NeoGluCO) study\u2014a randomised controlled trial.","volume":"12","author":"Laing","year":"2022","journal-title":"BMJ Open"},{"issue":"4","key":"zoi240529r9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/09732179211059607","article-title":"Diazoxide for the treatment of transitional neonatal hypoglycemia: a systematic review.","volume":"35","author":"Laing","year":"2021","journal-title":"J Neonatol"},{"issue":"3","key":"zoi240529r10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000251","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.","volume":"7","author":"Schulz","year":"2010","journal-title":"PLoS Med"},{"issue":"5","key":"zoi240529r11","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41372-020-0631-3","article-title":"Neonatal morbidity and small and large size for gestation: a comparison of birthweight centiles.","volume":"40","author":"Cartwright","year":"2020","journal-title":"J Perinatol"},{"issue":"5","key":"zoi240529r12","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1159\/000478696","article-title":"Population pharmacokinetics of diazoxide in children with hperinsulinemic hypoglycemia.","volume":"88","author":"Kizu","year":"2017","journal-title":"Horm Res Paediatr"},{"issue":"9","key":"zoi240529r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e20101","article-title":"Development and clinical application of a stability-indicating chromatography technique for the quantification of diazoxide.","volume":"9","author":"Purohit","year":"2023","journal-title":"Heliyon"},{"key":"zoi240529r14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jpeds.2020.02.079","article-title":"Glucose profiles in healthy term infants in the first 5 days: the Glucose in Well Babies (GLOW) Study.","volume":"223","author":"Harris","year":"2020","journal-title":"J Pediatr"},{"issue":"6","key":"zoi240529r15","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/apa.2018.107.issue-6","article-title":"Randomised controlled trial of diazoxide for small for gestational age neonates with hyperinsulinaemic hypoglycaemia provided early hypoglycaemic control without adverse effects.","volume":"107","author":"Balachandran","year":"2018","journal-title":"Acta Paediatr"},{"issue":"5","key":"zoi240529r16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/ped.2019.61.issue-5","article-title":"Exclusive breast-feeding and postnatal changes in blood sodium, ketone, and glucose levels.","volume":"61","author":"Futatani","year":"2019","journal-title":"Pediatr Int"},{"issue":"4","key":"zoi240529r18","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1172\/JCI30077","article-title":"Hypoglycemic neuronal death is triggered by glucose reperfusion and activation of neuronal NADPH oxidase.","volume":"117","author":"Suh","year":"2007","journal-title":"J Clin Invest"},{"issue":"1","key":"zoi240529r19","doi-asserted-by":"publisher","first-page":"8132","DOI":"10.1038\/s41598-019-44609-1","article-title":"Factors influencing glycaemic stability after neonatal hypoglycaemia and relationship to neurodevelopmental outcome.","volume":"9","author":"Burakevych","year":"2019","journal-title":"Sci Rep"},{"issue":"5","key":"zoi240529r20","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S0022-3476(77)81041-X","article-title":"Treatment of neonatal hypoglycemia with continuous intravenous glucose infusion.","volume":"91","author":"Lilien","year":"1977","journal-title":"J Pediatr"},{"issue":"9","key":"zoi240529r21","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqab121","article-title":"Decreased KATP channel activity contributes to the low glucose threshold for insulin secretion of rat neonatal islets.","volume":"162","author":"Yang","year":"2021","journal-title":"Endocrinology"},{"issue":"4","key":"zoi240529r22","doi-asserted-by":"publisher","first-page":"E352","DOI":"10.1152\/ajpendo.00377.2012","article-title":"Increased amino acid supply potentiates glucose-stimulated insulin secretion but does not increase \u00df-cell mass in fetal sheep.","volume":"304","author":"Gadhia","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5","key":"zoi240529r23","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.cmet.2020.04.004","article-title":"A nutrient-sensing transition at birth triggers glucose-responsive insulin secretion.","volume":"31","author":"Helman","year":"2020","journal-title":"Cell Metab"},{"key":"zoi240529r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2022.170748","article-title":"Urocortin3: local inducer of somatostatin release and bellwether of beta cell maturity.","volume":"151","author":"Flisher","year":"2022","journal-title":"Peptides"},{"issue":"7","key":"zoi240529r25","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1161\/CIRCRESAHA.112.300514","article-title":"KATP channels and cardiovascular disease: suddenly a syndrome.","volume":"112","author":"Nichols","year":"2013","journal-title":"Circ Res"},{"issue":"12","key":"zoi240529r26","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa543","article-title":"Management and appropriate use of diazoxide in infants and children with hyperinsulinism.","volume":"105","author":"Brar","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"zoi240529r27","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1038\/s41372-018-0218-4","article-title":"Prevalence and safety of diazoxide in the neonatal intensive care unit.","volume":"38","author":"Gray","year":"2018","journal-title":"J Perinatol"},{"issue":"9","key":"zoi240529r28","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1136\/archdischild-2023-325726","article-title":"Does the use of diazoxide for hyperinsulinaemic hypoglycaemia increase the risk of necrotising enterocolitis in neonates?","volume":"108","author":"Sol\u00eds-Garc\u00eda","year":"2023","journal-title":"Arch Dis Child"},{"key":"zoi240529r17","author":"Ennis","year":"2015"},{"key":"zoi240529r29","unstructured":"New Zealand Medicines Formulary. New Zealand Formulary for Children (NZFC), version 85. 2019. Accessed July 10, 2019. http:\/\/www.nzfchildren.org.nz"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2819962\/laing_2024_oi_240529_1717679855.54238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T15:22:00Z","timestamp":1718292120000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2819962"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.15764","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]}}}